ABOUT THE COMPANY

Mas Holding R&D

Mas Holding R&D is a group of Research and Development company which recently incorporated Halepce
R&D into the operation. The groups joint CEOs, Mr Metehan YEL and Mr Erdal Can ALKOLAR currently
have 260 active, 120 pending drug patent applications.
Specialising in neuroendocrine efficiency and central nervous system function optimising compounds, Mas
Holding R&D is the holder of the first Type-I Diabetes and anti-sarcopenic drugs produced in Turkey. Mas
Holding R&D is the only producer of 11-dimethylprotodioxin and anti-viral bioflavonoid glycolytic derivatives
both in Turkey and Europe. In 2014 Mas Holding R&D plans to apply for the patents of 180 new active
ingredients and the registration of 102 brands. On the other hand, we aim to remain as a source of pride for
Turkey on the international arena.
We have opened our entire resources to provide Turkish people and entire humanity access to
comprehensive health support. For this purpose we have made it a basic principle to continue providing
premium quality products at the lowest possible prices.
YeilAlkolar R&D currently employs 46 people, including with 33 technicians. By 2015 the company plans
open up to the global marketing with products ranging from the first domestic produce immunostimulant
formulation, 83 different anti-carcinogenic formulations that are based on 26 different mechanisms and 16
antibiotic formulations that are resistant to bacterial tolerance.
Our locomotive product is MYOSTIL hinders myostatin function by supressing follistatin expression and
based on this mechanism yields effective muscle development by affecting the anabolic steroid and growth
hormone combinations. We have completed brand registration applications for MYOSTIL in 122 countries.
MYOSTIL has also proven with it is effectiveness in age related muscle weakness and muscle mass loss
(senile sarcopenia) as well as muscle and bone sensity loss induced by destructive illnesses like AIDS and
various forms of cancer. We are committed to put MYOSTIL on the global market as a licensed drug.
Currently we take high pride in being the first company in Turkey and Europe to synthesize and hold patent
rights of hexa methyl-B- glucopyranoside derivatives, a very important core-GlcNAc3 inhibitor.
We are proud to say that YeilAlkolar R&D is dedicated to increase and maintain the quality of peoples
wellbeing.
Sincerely,
MAS HOLDNG Joint CEOs
Mr Metehan YEL and Mr Erdal Can ALKOLAR